CO151 Estimating the Benefit of Esketamine Nasal Spray Versus Real-World Treatment on Patient-Reported Functional Remission: Results From the Iceberg Study

Abstract

Treatment resistant depression (TRD) affects 10–30% of patients with major depressive disorder; most patients do not respond to real-world treatments (RWT).1 Esketamine nasal spray (NS), in combination with a selective serotonin or serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI), was recently approved for treatment of TRD. Esketamine NS has demonstrated significant benefit on response and remission versus RWT strategies;2 benefit on daily function remains to be established.